{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:56:27Z","timestamp":1793735787271,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41397-024-00353-y","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:02:59Z","timestamp":1728403379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3912-0520","authenticated-orcid":false,"given":"Samuel","family":"Huxley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hlatky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8366-8422","authenticated-orcid":false,"given":"Ryan","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Lerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verghese","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanjit","family":"Rihal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-3469","authenticated-orcid":false,"given":"Naveen L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"353_CR1","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet J, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA. 2010;304:1821\u201330.","journal-title":"JAMA"},{"key":"353_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","volume":"63","author":"M Castrichini","year":"2023","unstructured":"Castrichini M, Luzum JA, Pereira N. Pharmacogenetics of antiplatelet therapy. Annu Rev Pharmacol Toxicol. 2023;63:211\u201329.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"353_CR3","doi-asserted-by":"crossref","unstructured":"Brown SA, Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J Pers Med. 2018;8:8.","DOI":"10.3390\/jpm8010008"},{"key":"353_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","volume":"324","author":"NL Pereira","year":"2020","unstructured":"Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020;324:761\u201371.","journal-title":"JAMA"},{"key":"353_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jcin.2023.01.356","volume":"16","author":"BS Ingraham","year":"2023","unstructured":"Ingraham BS, Farkouh ME, Lennon RJ, So D, Goodman SG, Geller N, et al. Genetic-guided oral P2Y(12) inhibitor selection and cumulative ischemic events after percutaneous coronary intervention. JACC Cardiovasc Interv. 2023;16:816\u201325.","journal-title":"JACC Cardiovasc Interv"},{"key":"353_CR6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van \u2018t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med. 2019;381:1621\u201331.","journal-title":"N Engl J Med"},{"key":"353_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.121.003353","volume":"14","author":"V Parcha","year":"2021","unstructured":"Parcha V, Heindl BF, Li P, Kalra R, Limdi NA, Pereira NL, et al. Genotype-guided P2Y(12) inhibitor therapy after percutaneous coronary intervention: A Bayesian analysis. Circ Genom Precis Med. 2021;14:e003353.","journal-title":"Circ Genom Precis Med"},{"key":"353_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2327-8","volume":"17","author":"SL Visscher","year":"2017","unstructured":"Visscher SL, Naessens JM, Yawn BP, Reinalda MS, Anderson SS, Borah BJ. Developing a standardized healthcare cost data warehouse. BMC Health Serv Res. 2017;17:396.","journal-title":"BMC Health Serv Res"},{"key":"353_CR9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","volume":"84","author":"DY Lin","year":"1989","unstructured":"Lin DY, Wei LJ. The robust inference for the Cox Proportional Hazards Model. J Am Stat Assoc. 1989;84:1074\u2013978.","journal-title":"J Am Stat Assoc"},{"key":"353_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","volume":"11","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11:181\u201391.","journal-title":"JACC Cardiovasc Interv"},{"key":"353_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.117.002069","volume":"11","author":"CR Lee","year":"2018","unstructured":"Lee CR, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, et al. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circ Genom Precis Med. 2018;11:e002069.","journal-title":"Circ Genom Precis Med"},{"key":"353_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","volume":"14","author":"NL Pereira","year":"2021","unstructured":"Pereira NL, Rihal C, Lennon R, Marcus G, Shrivastava S, Bell MR, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y(12) inhibitor therapy. a meta-analysis. JACC Cardiovasc Interv. 2021;14:739\u201350.","journal-title":"a meta-analysis. JACC Cardiovasc Interv"},{"key":"353_CR13","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","volume":"397","author":"M Galli","year":"2021","unstructured":"Galli M, Benenati S, Capodanno D, Franchi F, Rollini F, D\u2019Amario D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021;397:1470\u201383.","journal-title":"Lancet"},{"key":"353_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-017-6720-7","volume":"31","author":"BJ Borah","year":"2017","unstructured":"Borah BJ, Pereira N, Farkouh ME. Personalizing antiplatelet therapies for acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI): Are they cost-effective? Cardiovasc Drugs Ther. 2017;31:1\u20133.","journal-title":"Cardiovasc Drugs Ther"},{"key":"353_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/jth.12059","volume":"11","author":"A Lala","year":"2013","unstructured":"Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost. 2013;11:81\u201391.","journal-title":"J Thromb Haemost"},{"key":"353_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10557-019-06896-8","volume":"33","author":"K Kim","year":"2019","unstructured":"Kim K, Touchette DR, Cavallari LH, Ardati AK, DiDomenico RJ. Cost-effectiveness of strategies to personalize the selection of P2Y(12) inhibitors in patients with acute coronary syndrome. Cardiovasc Drugs Ther. 2019;33:533\u201346.","journal-title":"Cardiovasc Drugs Ther"},{"key":"353_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","volume":"43","author":"M Galli","year":"2022","unstructured":"Galli M, Benenati S, Franchi F, Rollini F, Capodanno D, Biondi-Zoccai G, et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J. 2022;43:959\u201367.","journal-title":"Eur Heart J"},{"key":"353_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1074248420902298","volume":"25","author":"S AlMukdad","year":"2020","unstructured":"AlMukdad S, Elewa H, Al-Badriyeh D. Economic evaluations of CYP2C19 genotype-guided antiplatelet therapy compared to the universal use of antiplatelets in patients with acute coronary syndrome: A systematic review. J Cardiovasc Pharmacol Ther. 2020;25:201\u201311.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"353_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40256-021-00496-4","volume":"22","author":"DMF Claassens","year":"2022","unstructured":"Claassens DMF, van Dorst PWM, Vos GJA, Bergmeijer TO, Hermanides RS, van \u2018t Hof AWJ, et al. Cost effectiveness of a CYP2C19 genotype-guided strategy in patients with acute myocardial infarction: results from the POPular Genetics Trial. Am J Cardiovasc Drugs. 2022;22:195\u2013206.","journal-title":"Am J Cardiovasc Drugs"},{"key":"353_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/ehjqcco\/qcac031","volume":"9","author":"OM Dong","year":"2023","unstructured":"Dong OM, Friede KA, Chanfreau-Coffinier C, Voora D. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. Eur Heart J Qual Care Clin Outcomes. 2023;9:249\u201357.","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00353-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00353-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00353-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:06:44Z","timestamp":1734606404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00353-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["353"],"URL":"https:\/\/doi.org\/10.1038\/s41397-024-00353-y","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BB is a consultant for Exact Sciences and Boehringer Ingelheim on projects unrelated to this project.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}